Pfizer leases Puerto Rico plant to medical marijuana producer

辉瑞向医用大麻公司租赁闲置工厂,大麻公司成药企转移过剩产能新对象

2019-06-27 16:04:00 FiercePharma

本文共1062个字,阅读需3分钟

Looks like unloading surplus manufacturing sites to the cannabis industry is turning into a budding business for pharma. At the same time Novartis was negotiating a deal to sell a Colorado plant to a CBD producer, Pfizer was leasing a facility to a medical marijuana supplier.  Vireo Health says it has leased a 40,000 square foot facility in Barceloneta, Puerto Rico from Pfizer to handle its cultivation and processing operations.  “We are thrilled to expand into the Commonwealth of Puerto Rico, one of the largest pharmaceutical hubs in the world,” Vireo CEO Kyle Kingsley, M.D., said in a statement. “This expansion will give us access to the island’s deep pool of talented professionals, create a wide variety of jobs, and allow us to help many more patients.” Pfizer closed the facility in 2017 but still has two other facilities on the island.  "Surplus pharma facilities are ideal for cannabis companies because we require many of the same types of machinery and outfitting – strong security systems, clean rooms, testing facilities, laboratories," Vireo spokesperson Albe Zakes said in an email.  The lease agreement came the same week that Novartis closed a deal to sell its Sandoz plant in Broomfield, Colorado to a Colorado CBD maker. Mile High Labs says it paid Novartis $18.75 million for the 400,000-square-foot production facility near Boulder, along with all of the equipment.  Mile High will manufacture private-label CBD products at the facility. A spokesman said it expects to be up and running with 100 employees in a few months and hopes to hire some of the former Sandoz employees.  “Many analysts have been openly wondering when pharma would take over the CBD industry, but what if the opposite were true?” Mile High founder Stephen Mueller said in a statement about the deal. Pharma has a lot of excess manufacturing capacity that it has been idling. Novartis CEO Vas Narasimhan called 2018 a transformative year in manufacturing for the Swiss company which closed or sold eight facilities and restructured eight others, whacking about 2,000 jobs in the process. Teva has closed a slew of plants in the last two years to cut costs.  Bristol-Myers Squibb this month said it was selling a plant in Anagni, Italy to Catalent, which will take on 700 employees. The facility makes a wide variety of products including cancer and cardiology drugs, which Catalent will continue to produce for Bristol-Myers.
看起来,向大麻行业卸下过剩的生产基地正在成为医药行业的新兴业务。与此同时,诺华(Novartis)公司正在谈判一项向 CBD 生产商出售科罗拉多工厂的协议,辉瑞(Pfizer)公司正在向一家医用大麻供应商租赁一家工厂。 Vireo Health 表示,它已从辉瑞(Pfizer)公司租赁了位于波多黎各 Barceloneta 的一家4万平方英尺的工厂,以处理其种植和加工业务。 Vireo 首席执行官凯尔·金斯利( Kyle Kingsley )在一份声明中表示:“我们很高兴扩展到波多黎各这个世界上最大的医药中心之一。”“这种扩张将使我们有机会接触到台湾的人才库,创造各种各样的就业机会,并让我们帮助更多的病人。” 辉瑞(Pfizer)在2017年关闭了该工厂,但在岛上还有另外两家工厂。 Vireo 发言人 AlbeZakes 在一封电子邮件中说:“制药设备过剩是大麻公司的理想选择,因为我们需要很多相同类型的机器和设备——强大的安全系统、洁净室、测试设施、实验室。” 就在租赁协议达成的同一周,诺华( Novartis )完成了向科罗拉多 CBD 制造商出售其位于科罗拉多州 Broomfield 的 Sandoz 工厂的交易。Mile High Labs 表示,它向诺华(Novartis)支付了1875万美元,购买了 Boulder 附近40万平方英尺的生产设施以及所有设备。 Mile High 将在工厂生产自有品牌的 CBD 产品。一位发言人说,该公司预计将在几个月内雇佣100名员工,并希望雇佣一些前 Sandoz 员工。 “许多分析师一直在公开质疑制药公司何时会接管 CBD 行业,但如果情况相反,情况又如何呢?Mile High 创始人斯蒂芬•穆勒( Stephen Mueller )在一份关于这笔交易的声明中表示。 制药公司有很多过剩的生产能力,它一直在闲置。诺华( Novartis )首席执行长纳拉希姆( Vas Narasimhan )称,2018年是这家瑞士公司制造业转型的一年。该公司关闭或出售了8家工厂,并重组了另外8家工厂,在此过程中造成约2000个就业岗位流失。梯瓦(Teva)在过去两年关闭了一系列工厂以削减成本。 百时美施贵宝( Bristol-MyersSquibb )本月表示,将把位于意大利阿纳尼( Anagni )的一家工厂出售给 Catalent ,后者将雇佣700名员工。该工厂生产各种各样的产品,包括癌症和心脏病学药物, Catalent 将继续为百时美施贵宝生产。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文